What's Happening?
Newron Pharmaceuticals has initiated enrollment in its Phase III ENIGMA-TRS program, evaluating evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). The study will involve 600 patients across multiple international sites, assessing the efficacy, tolerability, and safety of evenamide compared to placebo. Evenamide, a glutamate modulator, offers a new therapeutic option for TRS patients who do not respond to current antipsychotic treatments.
Why It's Important?
The development of evenamide as a treatment for TRS addresses a significant unmet need in schizophrenia care. A substantial portion of patients with schizophrenia are resistant to existing antipsychotic medications, necessitating new treatment approaches. Evenamide's unique mechanism of action could provide relief for these patients, improving their quality of life and reducing healthcare costs associated with managing TRS. Successful trials could lead to broader acceptance and use of glutamatergic modulation in psychiatric treatment.
AD
What's Next?
The ENIGMA-TRS program will continue with a 52-week study, with initial results expected in late 2026. Newron plans to expand the trial to additional sites, including the U.S., pending FDA approval. The company aims to demonstrate evenamide's efficacy and safety, potentially leading to regulatory approval and commercialization.
